ENTX
Price
$2.03
Change
-$0.05 (-2.40%)
Updated
Aug 5, 04:59 PM (EDT)
Capitalization
91.81M
3 days until earnings call
XENE
Price
$34.40
Change
+$1.24 (+3.74%)
Updated
Aug 5, 04:59 PM (EDT)
Capitalization
2.54B
2 days until earnings call
Interact to see
Advertisement

ENTX vs XENE

Header iconENTX vs XENE Comparison
Open Charts ENTX vs XENEBanner chart's image
Entera Bio
Price$2.03
Change-$0.05 (-2.40%)
Volume$800
Capitalization91.81M
Xenon Pharmaceuticals
Price$34.40
Change+$1.24 (+3.74%)
Volume$15.85K
Capitalization2.54B
ENTX vs XENE Comparison Chart in %
Loading...
ENTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ENTX vs. XENE commentary
Aug 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ENTX is a StrongBuy and XENE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 06, 2025
Stock price -- (ENTX: $2.08 vs. XENE: $33.16)
Brand notoriety: ENTX and XENE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ENTX: 130% vs. XENE: 169%
Market capitalization -- ENTX: $94.54M vs. XENE: $2.54B
ENTX [@Biotechnology] is valued at $94.54M. XENE’s [@Biotechnology] market capitalization is $2.54B. The market cap for tickers in the [@Biotechnology] industry ranges from $213.02B to $0. The average market capitalization across the [@Biotechnology] industry is $2.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ENTX’s FA Score shows that 0 FA rating(s) are green whileXENE’s FA Score has 1 green FA rating(s).

  • ENTX’s FA Score: 0 green, 5 red.
  • XENE’s FA Score: 1 green, 4 red.
According to our system of comparison, XENE is a better buy in the long-term than ENTX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ENTX’s TA Score shows that 7 TA indicator(s) are bullish while XENE’s TA Score has 5 bullish TA indicator(s).

  • ENTX’s TA Score: 7 bullish, 3 bearish.
  • XENE’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, ENTX is a better buy in the short-term than XENE.

Price Growth

ENTX (@Biotechnology) experienced а +0.97% price change this week, while XENE (@Biotechnology) price change was +7.07% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.39%. For the same industry, the average monthly price growth was +19.63%, and the average quarterly price growth was +13.22%.

Reported Earning Dates

ENTX is expected to report earnings on Nov 06, 2025.

XENE is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+2.39% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XENE($2.54B) has a higher market cap than ENTX($91.8M). ENTX YTD gains are higher at: -1.887 vs. XENE (-15.408). ENTX has higher annual earnings (EBITDA): -10.05M vs. XENE (-290.36M). XENE has more cash in the bank: 550M vs. ENTX (12.6M). ENTX has less debt than XENE: ENTX (220K) vs XENE (8.68M). XENE has higher revenues than ENTX: XENE (7.5M) vs ENTX (223K).
ENTXXENEENTX / XENE
Capitalization91.8M2.54B4%
EBITDA-10.05M-290.36M3%
Gain YTD-1.887-15.40812%
P/E RatioN/AN/A-
Revenue223K7.5M3%
Total Cash12.6M550M2%
Total Debt220K8.68M3%
FUNDAMENTALS RATINGS
ENTX vs XENE: Fundamental Ratings
ENTX
XENE
OUTLOOK RATING
1..100
9259
VALUATION
overvalued / fair valued / undervalued
1..100
50
Fair valued
50
Fair valued
PROFIT vs RISK RATING
1..100
9445
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
5985
P/E GROWTH RATING
1..100
1005
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ENTX's Valuation (50) in the Pharmaceuticals Major industry is in the same range as XENE (50) in the Biotechnology industry. This means that ENTX’s stock grew similarly to XENE’s over the last 12 months.

XENE's Profit vs Risk Rating (45) in the Biotechnology industry is somewhat better than the same rating for ENTX (94) in the Pharmaceuticals Major industry. This means that XENE’s stock grew somewhat faster than ENTX’s over the last 12 months.

XENE's SMR Rating (100) in the Biotechnology industry is in the same range as ENTX (100) in the Pharmaceuticals Major industry. This means that XENE’s stock grew similarly to ENTX’s over the last 12 months.

ENTX's Price Growth Rating (59) in the Pharmaceuticals Major industry is in the same range as XENE (85) in the Biotechnology industry. This means that ENTX’s stock grew similarly to XENE’s over the last 12 months.

XENE's P/E Growth Rating (5) in the Biotechnology industry is significantly better than the same rating for ENTX (100) in the Pharmaceuticals Major industry. This means that XENE’s stock grew significantly faster than ENTX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ENTXXENE
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
77%
MACD
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
70%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
74%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
75%
Advances
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 20 days ago
72%
Declines
ODDS (%)
Bearish Trend 12 days ago
90%
Bearish Trend 5 days ago
73%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
72%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
ENTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SLVRX34.69N/A
N/A
Columbia Select Large Cap Value R
RRCOX60.93N/A
N/A
T. Rowe Price U.S. Equity Research R
TETAX12.89N/A
N/A
RBC Enterprise A
KCVIX17.74N/A
N/A
Knights of Columbus Large Cap Value I
MLCPX8.48N/A
N/A
MainGate MLP C

ENTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, ENTX has been loosely correlated with STOK. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if ENTX jumps, then STOK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENTX
1D Price
Change %
ENTX100%
+6.67%
STOK - ENTX
33%
Loosely correlated
+1.78%
JSPR - ENTX
32%
Poorly correlated
+3.12%
OPORF - ENTX
31%
Poorly correlated
N/A
XENE - ENTX
30%
Poorly correlated
+8.72%
IMNM - ENTX
30%
Poorly correlated
+3.40%
More

XENE and

Correlation & Price change

A.I.dvisor indicates that over the last year, XENE has been loosely correlated with IDYA. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if XENE jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XENE
1D Price
Change %
XENE100%
+8.72%
IDYA - XENE
59%
Loosely correlated
+3.09%
CRNX - XENE
54%
Loosely correlated
+1.36%
ATXS - XENE
52%
Loosely correlated
+5.03%
NRIX - XENE
51%
Loosely correlated
+2.17%
DNLI - XENE
50%
Loosely correlated
+7.44%
More